(PRQR) ProQR Therapeutics N.V. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRQR) ProQR Therapeutics N.V. Complete Analysis Pack
ProQR Therapeutics Business Model Canvas: Strategic Blueprint in Brief
Unlock the full strategic blueprint behind ProQR Therapeutics N.V.’s business model. This concise Business Model Canvas breaks down how the company creates value, builds partnerships, and navigates the biotech landscape. Ideal for investors, analysts, and strategists seeking actionable insights—get the full version for a deeper, ready-to-use view.
Partnerships
Eli Lilly collaboration
The Eli Lilly collaboration gave ProQR Therapeutics N.V. a $75 million upfront payment and a path to discover, advance, and commercialize RNA-editing medicines for genetic diseases in the liver and nervous system. It also strengthened external validation of ProQR’s platform and expanded its partnering reach with a global pharma company.
Radboud UMC license
ProQR Therapeutics N.V.’s Radboud UMC license gives it an academic source of RNA-therapy know-how, helping turn translational research into proprietary programs for rare genetic disorders. This link also strengthens its intellectual property base, since the company’s origin traces back to Radboud UMC research on RNA-based medicines and disease-focused development.
Inserm Transfert SA license
Inserm Transfert SA is ProQR Therapeutics N.V.'s France-based tech-transfer and licensing partner, giving access to research assets and IP tied to its RNA pipeline. This kind of deal is standard in early RNA drug discovery, where licensed science and academic collaboration can reduce upfront R&D risk and widen target access.
Ionis Pharmaceuticals license
Ionis Pharmaceuticals is a key external IP partner for ProQR Therapeutics N.V., adding nucleic-acid drug know-how that supports platform and program work. This license helps ProQR widen its RNA therapeutics options without building every capability in-house.
- External IP access
- RNA science depth
- Broader program optionality
- Alliance-led innovation
Leiden University Medical Center license
Leiden University Medical Center is ProQR Therapeutics N.V.’s local academic partner in Leiden, Netherlands. The license supports discovery in genetic medicine and gives ProQR access to translational expertise and research capabilities close to its headquarters, which helps move early science toward clinic-ready programs.
- Local Dutch academic fit
- Research access and expertise
- Supports genetic medicine discovery
- Aligned with Leiden HQ
ProQR’s Strategic Partners Fuel RNA-Editing Growth
ProQR Therapeutics N.V. relies on a small but high-value partner base: Eli Lilly brought a $75 million upfront deal for RNA-editing work, while Radboud UMC, Inserm Transfert SA, Ionis Pharmaceuticals, and Leiden University Medical Center supply academic IP, translational science, and external RNA know-how.
Together, these partnerships reduce early R&D risk and widen ProQR Therapeutics N.V.’s program reach across liver, nervous system, and rare genetic disease targets.
| Partner | Value |
|---|---|
| Eli Lilly | $75 million upfront |
| Radboud UMC | Core RNA IP |
| Ionis Pharmaceuticals | External nucleic-acid know-how |
What is included in the product
Detailed Word Document
A concise, real-world BMC overview of ProQR Therapeutics N.V. covering its RNA-based drug development model, partners, channels, and value proposition.
Customizable Excel Spreadsheet
Quickly maps ProQR Therapeutics’ business model to spot key pain points and opportunities at a glance.
Reference Sources
Provides a clear source trail for ProQR Therapeutics N.V., boosting credibility and making decisions easier to verify.
Activities
RNA therapy discovery
ProQR Therapeutics N.V. uses RNA therapy discovery to identify and design RNA-based drug candidates for high-unmet-need genetic disorders. This upstream work combines biology-driven target selection and medicinal chemistry; it matters in a market where genetic disorders make up about 80% of rare diseases, or 7,000-plus conditions.
Phase II/III clinical development
ProQR Therapeutics N.V. is advancing Sepofarsen in the ILLUMINATE program and Ultevursen in Phase II/III studies, where clinical execution means enrolling patients, dosing them, and tracking endpoints on schedule. This is the key late-stage value driver, since one successful registrational readout can move a program toward approval.
Axiomer platform development
ProQR Therapeutics N.V. keeps Axiomer as its proprietary RNA base-editing engine, with 2025 work focused on building new programs beyond today’s assets and widening reach across liver and nervous system targets. That platform-first model supports longer-term economics by creating more shots on goal from one technology stack, not just one product.
Partnered research and licensing
ProQR Therapeutics N.V. uses partnered research and licensing to manage university and biopharma ties, while negotiating rights, milestones, and scope to keep programs moving. This model supports access to outside science and commercialization paths, and it is central to non-dilutive growth.
- External science, lower cash burn
- Milestones tie value to progress
- Licensing can expand reach
Regulatory and data management
Regulatory and data management at ProQR Therapeutics N.V. turns Phase 1/2 and preclinical results into clean regulator-ready packages, then tracks safety, efficacy, and biomarker signals to guide trial go/no-go calls and future filings. In rare-disease work, where patient pools are tiny, fast, accurate data review can decide whether a program moves ahead.
- Prepares FDA/EMA submission packages
- Reviews safety and biomarker data
- Supports trial and filing decisions
ProQR’s RNA Pipeline Targets Rare Diseases and Late-Stage Clinical Wins
ProQR Therapeutics N.V. mainly designs RNA therapies, advances Sepofarsen and Ultevursen through clinical trials, and expands Axiomer into new programs. Its key work is target selection, trial execution, and data packages for FDA and EMA filings, with rare diseases covering 7,000+ conditions.
| Key activity | Data point |
|---|---|
| Rare-disease focus | 7,000+ conditions |
| Late-stage programs | Sepofarsen, Ultevursen |
| Platform engine | Axiomer |
What You See Is What You Get
Business Model Canvas
This ProQR Therapeutics N.V. Business Model Canvas preview is the actual document you’ll receive after purchase, not a sample or placeholder. What you see here is a direct snapshot of the final file, with the same structure, formatting, and content. Once you complete your order, you’ll get full access to this exact document, ready to use right away.
Resources
Sepofarsen asset
Sepofarsen is ProQR Therapeutics N.V.’s lead antisense asset for CEP290-related LCA10 and its most advanced ophthalmology program. It is in Phase II/III testing and remains a key near-term value driver for the Company.
Ultevursen asset
Ultevursen is ProQR Therapeutics N.V.'s lead clinical asset for USH2A-mediated retinitis pigmentosa and Usher syndrome, and it is in Phase II/III evaluation. It broadens the ophthalmology pipeline in a severe rare-disease market where USH2A variants are a major inherited cause of vision loss, affecting thousands of patients worldwide.
Axiomer platform
Axiomer is ProQR Therapeutics N.V.'s proprietary RNA base-editing platform and the core engine for future drug discovery. It supports differentiated science and can seed multiple programs over time, giving Company Name a repeatable way to build a broader pipeline from one technology base.
Licensed intellectual property
ProQR Therapeutics N.V. relies on licensed intellectual property from Radboud UMC, Inserm Transfert SA, Ionis Pharmaceuticals, and LUMC to secure access to core RNA-editing science and lower early-stage R&D risk. That IP base also helps defend ProQR Therapeutics N.V.’s position by blocking easy copycats and supporting its pipeline before heavy in-house spending begins.
- Enables key RNA-editing know-how
- Reduces upfront development friction
- Strengthens competitive moat
- Supports pipeline formation and licensing
Leiden headquarters and team
ProQR Therapeutics N.V.’s Leiden headquarters in the Netherlands anchors its operating base, housing management and research and development oversight. It also helps coordinate global collaborations, which matters for a rare-disease RNA pipeline built on a small, central team.
- Leiden, Netherlands: main corporate base
- Hosts management and R&D oversight
- Supports global partner coordination
ProQR’s Late-Stage Eye Assets and Axiomer Platform Drive Growth
ProQR Therapeutics N.V.’s key resources are its two late-stage ophthalmology assets, sepofarsen and ultevursen, plus the Axiomer RNA base-editing platform that can generate new programs. Its licensed IP and Leiden, Netherlands base support a small but scalable R&D model focused on rare eye disease.
| Key resource | Role |
|---|---|
| Sepofarsen | Phase II/III lead asset |
| Ultevursen | Phase II/III lead asset |
| Axiomer | RNA base-editing platform |
Value Propositions
RNA-based genetic medicines
ProQR Therapeutics N.V. builds RNA-based genetic medicines that act at the RNA level to change disease biology, not just ease symptoms. This fits rare inherited disorders, which affect about 300 million people worldwide and are genetic in over 80% of cases, and it stands apart from small-molecule drugs by targeting the faulty message itself.
Late-stage rare disease pipeline
ProQR Therapeutics N.V. has two lead rare-disease assets in Phase II/III: sepofarsen for LCA10 and ultevursen for USH2A-mediated retinal disease. That late-stage setup can shorten time to a value inflection, because both programs are already past early discovery and closer to pivotal data and potential partnering or approval steps.
Platform-driven pipeline expansion
Axiomer gives ProQR Therapeutics N.V. a repeatable RNA-editing engine, and the company said in 2025 it was advancing multiple Axiomer programs, which supports new assets beyond today’s pipeline. That platform can extend use across tissues and preserve strategic flexibility as new targets move from discovery to clinic.
Strong partner-backed science
ProQR Therapeutics N.V. uses partner-backed science to validate its RNA-editing platform, with academic and industry links adding outside expertise, specialty tools, and stronger credibility. That support helps de-risk discovery before costly scale-up and makes the model easier for stakeholders to trust.
- External partners add science depth
- Licensing supports technical validation
- Shared assets reduce R&D risk
- Credibility improves with investors
Precision focus on unmet need
ProQR Therapeutics N.V. focuses on genetic disorders with few or no approved therapies, especially inherited eye diseases. That fits orphan-drug economics: rare-disease markets are small, but high unmet need can support premium pricing, and ProQR reported €18.8 million in cash and equivalents at 31 Dec 2025, keeping development tied to its precision-medicine pipeline.
- Targets rare, high-need genetic disease
- Centers on ophthalmology and inherited conditions
- Fits orphan-drug pricing and economics
- Uses precision focus to address unmet need
ProQR’s RNA Pipeline Targets Rare Disease Upside
ProQR Therapeutics N.V. gives value through RNA medicines that target the disease-causing message in rare genetic disorders, especially inherited eye disease, where unmet need is high and pricing power can be stronger. Its late-stage sepofarsen and ultevursen assets, plus the Axiomer RNA-editing platform, create both near-term and longer-term upside.
| Metric | Value |
|---|---|
| Cash and equivalents | €18.8 million |
| Lead assets | 2 Phase II/III |
| Platform | Axiomer RNA editing |
Customer Relationships
Partner-to-partner collaboration
ProQR Therapeutics N.V. runs a B2B partner model, using research and license deals built around shared milestones, data exchange, and review rights. In biotech, this setup often adds upfront cash plus milestone payments and royalties, which is why partner quality can matter as much as the science.
Clinical-site engagement
Clinical-site engagement keeps ProQR Therapeutics N.V. investigators, hospitals, and trial centers aligned so patients can be enrolled fast and protocols run cleanly. This ongoing medical and operational coordination is especially critical in Phase II/III studies, where each site can affect timelines, data quality, and endpoint readout.
Regulator-facing communication
ProQR Therapeutics N.V. keeps close, structured contact with health authorities to align on safety, efficacy, and development plans; in rare-disease trials, even small cohorts can decide clinical progression, so regulator updates are not optional. This is especially important when patient numbers are limited and every protocol change must be cleared fast.
Scientific community interaction
ProQR Therapeutics N.V. uses scientific community interaction to publish data, present findings, and build trust with researchers and clinicians; this helps attract partners and talent, and supports external validation of its RNA-editing platform. In 2025, that kind of visibility mattered as the Company Name kept advancing its pipeline through public disclosures and conference updates.
- Publishes data and presents findings
- Builds researcher and clinician awareness
- Helps attract partners and talent
- Supports platform validation
Investor and shareholder relations
ProQR Therapeutics N.V. depends on capital markets because it is still pre-commercial, so investor and shareholder relations are key. Regular updates on pipeline, trial data, and partnership progress help keep trust high and visibility clear when the company is funding R&D instead of product sales.
- Capital access is critical for biotech.
- Pipeline and trial updates drive confidence.
- Partnership news can support funding.
Partnerships Power ProQR’s 2025 Trial and Funding Outlook
Customer relationships at ProQR Therapeutics N.V. center on close ties with partners, trial sites, regulators, and the scientific community. In 2025, these links mattered because the Company Name still depended on external validation, clean trial execution, and funding confidence rather than product sales.
| 2025 focus | Why it matters |
|---|---|
| Partners | Milestones, data, royalties |
| Sites | Faster enrollment |
| Regulators | Clear go-no go path |
Channels
Clinical trial sites
Clinical trial sites are ProQR Therapeutics N.V.’s main channel for Sepofarsen and Ultevursen. Specialist centers recruit patients, deliver dosing, and run follow-up, which is critical in rare-eye trials where each site may track only a small patient pool but still generate the core efficacy and safety data.
Licensing agreements
Licensing agreements are ProQR Therapeutics N.V.’s main way to monetize its RNA-editing IP and tech access, turning research into structured deals with universities and pharma partners. This channel supports downstream commercialization and, in 2025, fit a model where ProQR still had no marketed product revenue and relied on collaboration-based funding.
Scientific publications
Scientific publications share peer-reviewed proof of concept and clinical results with researchers, clinicians, and partners, helping ProQR Therapeutics N.V. build credibility for RNA therapeutics. They also widen rare-disease awareness beyond the clinic, where one paper can reach global audiences through journals and databases like PubMed.
Medical conferences
Medical conferences let ProQR Therapeutics N.V. show clinical data to industry and academic audiences, which helps build partnerships, investor interest, and pipeline visibility. This channel matters in biotech: in 2024, BIO and EBD Group reported 10,000+ partnering meetings at major life-science conferences, showing how often deal flow starts there.
- Shares data with scientists and buyers
- Supports BD and investor outreach
- Raises pipeline visibility fast
- Common biotech deal channel
Corporate website and IR
ProQR Therapeutics N.V.’s corporate website and Investor Relations page is the company’s main source for pipeline updates, press releases, SEC filings, and governance details. It serves investors, partners, and recruits as the central digital hub for a listed biotech.
- Pipeline, news, governance
- Primary channel for IR updates
- Supports investors, partners, recruits
- Central online presence
ProQR’s Key Channels Power RNA Trials, Deals, and Investor Reach
ProQR Therapeutics N.V. uses specialist trial sites, licensing partners, publications, conferences, and its website to move RNA data and deals. In 2025, it still had no marketed product revenue, so these channels stayed key for funding, recruitment, and partner reach.
| Channel | Use |
|---|---|
| Trial sites | Patient dosing |
| Licensing | IP monetization |
| Website | IR hub |
Customer Segments
Rare disease patients
Rare disease patients are ProQR Therapeutics N.V.'s core medical-need segment: people with genetic disorders such as LCA10 and USH2A-related disease, where even small patient groups matter. LCA is often cited at about 1 in 40,000 births, and the same precision-medicine base can extend to future liver and nervous-system programs.
Ophthalmology specialists
Ophthalmology specialists are ProQR Therapeutics N.V.’s key professional audience because they diagnose and manage inherited retinal diseases, which affect about 1 in 2,000 people and are linked to more than 270 genes. They drive referral, trial enrollment, and early adoption of future therapies, especially in rare-disease centers.
Hospitals and trial centers
Hospitals and trial centers are ProQR Therapeutics N.V.’s operational customers in Phase II/III studies, because they handle patient recruitment and protocol delivery. In rare-disease care, these sites often sit in multi-site networks that can be small but highly specialized; for example, ProQR’s late-stage clinical work depends on these centers to run 2 key jobs: enroll patients and execute the study plan.
Pharma and biotech partners
Pharma and biotech partners are ProQR Therapeutics N.V.'s core B2B customers: companies that want RNA assets or access to the Axiomer platform. Partners such as Eli Lilly can bring funding, drug-development expertise, and a clear path to commercialization.
- RNA assets and platform access
- Funding plus technical know-how
- Commercialization support
- Major B2B revenue channel
Academic and research institutions
Academic and research institutions are a core innovation source for ProQR Therapeutics N.V., with universities and medical centers contributing IP, disease biology, and translational science. Radboud UMC and LUMC help move discovery work into human-relevant studies, where early data can de-risk RNA-editing programs.
- Two key partners: Radboud UMC and LUMC
- Source of IP and science
- Supports discovery and translational research
- Feeds ProQR’s innovation pipeline
ProQR’s rare-disease network: patients, partners, and precision science
ProQR Therapeutics N.V. serves rare-disease patients, especially inherited retinal disease groups like LCA and USH2A, plus the specialists and trial sites that diagnose, treat, and enroll them. Its business also depends on pharma partners and academic centers that supply funding, science, and development support.
| Segment | Key data |
|---|---|
| Patients | LCA about 1 in 40,000 births |
| IRD audience | About 1 in 2,000 people; 270+ genes |
| Partners | RNA assets, funding, commercialization |
Cost Structure
Clinical trial spending
Clinical trial spending is a major cost driver for ProQR Therapeutics N.V., especially in Phase II/III programs, where enrollment, site fees, monitoring, and data analysis can push single studies into the tens of millions of dollars. Rare-disease trials usually cost more because patient recruitment is harder and slower, but this spend is essential to advance candidates and generate registrational data.
R&D and platform development
In 2025, ProQR Therapeutics N.V. kept R&D and platform development as its core operating cost, funding RNA discovery and Axiomer research. The spend covers lab work, assays, and optimization, and it is aimed at building future pipeline assets.
Manufacturing and CMC
Manufacturing and CMC covers drug substance and drug product work, plus the quality systems and technical development needed to make clinical supply for ProQR Therapeutics N.V. trial candidates. For RNA medicines, this is a key cost block because each batch needs tight control of purity, stability, and release testing before patients can receive it.
It also links directly to trial scale-up, since clinical programs can move from small batch runs to larger GMP lots as data read out.
Personnel and overhead
Personnel and overhead are a fixed-cost core for ProQR Therapeutics N.V.: scientific, clinical, regulatory, and admin teams, plus Leiden headquarters, are needed to run partnered programs and keep development moving. In FY2025, this cost bucket remained the main operating burden for a development-stage biotech, with no product sales to offset it.
- Scientific and regulatory staff drive spend
- Leiden HQ adds steady overhead
- Partner management needs lean admin support
- Fixed costs matter before revenue arrives
IP and collaboration costs
ProQR Therapeutics N.V. spends on license fees, diligence, and legal work to protect and widen its patent base; that matters in a platform biotech where each new RNA-editing program can mean new filings, freedom-to-operate checks, and contract reviews. These costs also cover partner setup and deal execution, so they rise as collaboration activity grows.
- License and patent protection costs
- Legal, diligence, and contract management
- Partnership execution for platform scaling
FY2025 Burn Stayed Biotech-Heavy as R&D and Trials Drove Costs
FY2025 cost structure stayed biotech-heavy: R&D, Axiomer platform work, and clinical development were the main cash uses, with no product sales to offset them. Clinical ops, CMC, and GMP supply scale up with each RNA program, while patents, legal work, and partner setup add fixed and deal-linked costs.
| Cost block | FY2025 role |
|---|---|
| R&D | Largest spend |
| Trials | Phase II/III heavy |
| CMC | Clinical supply |
| IP/legal | Patent and deal work |
Revenue Streams
Collaboration payments
ProQR Therapeutics N.V. uses collaboration payments as cash from research partnerships and joint programs, typically funded work under external agreements, so it adds non-dilutive financing before product launch. This stream was still small in the latest reported period, with revenue from collaboration agreements at a low base while the company advanced its pipeline.
Upfront license fees
Upfront license fees are cash paid when ProQR Therapeutics N.V. grants IP rights, and they are a common biotech deal tool to monetize science early. In 2025, ProQR’s partnership with Eli Lilly and Company included a $75 million upfront payment, showing how this stream fits ProQR Therapeutics N.V.’s partnering model and reduces near-term funding pressure.
Milestone payments
Milestone payments are ProQR Therapeutics N.V.’s classic biotech alliance revenue: cash is received when research, clinical, or regulatory targets are hit, so income tracks technical de-risking instead of sales volume. For example, a development milestone can trigger payment after a trial readout or IND/CTA step, which is standard in partnered rare-disease programs.
Royalties on future sales
Royalties on future sales could become a long-term income stream for ProQR Therapeutics N.V. if partnered RNA-editing assets reach the market, but the cash only starts after approval and commercial launch. In 2025, this revenue line was still immaterial, so upside depends on partner execution, label breadth, and end-market uptake.
- Post-approval income only
- Partner-led commercialization
- Revenue scales with sales
- Near-term impact is low
Future product sales
Future product sales for ProQR Therapeutics N.V. are upside only: the company had no approved product revenue in 2025, and its 2025 full-year revenue was $6.7 million, mainly from collaborations. If a candidate wins approval and launch, sales would depend on market access, pricing, and label breadth, with product sales becoming meaningful only after commercialization.
- Not current core revenue
- Depends on approval and access
- Upside if commercialization succeeds
ProQR’s Revenue Still Hinges on Collaborations and Big Deal Payments
ProQR Therapeutics N.V. generates most revenue from collaboration agreements, with 2025 full-year revenue of $6.7 million, mainly from partnered R&D work. The model is still milestone- and license-driven, and future royalties or product sales remain immaterial until a partnered asset reaches market.
| Revenue stream | 2025 data | Role |
|---|---|---|
| Collaboration revenue | $6.7 million | Main cash source |
| Upfront license fee | $75 million | 2025 Lilly deal |
| Royalties and product sales | Immateral | Future upside |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.